Accelerating Clinical Translation of Antibody-Drug Conjugates with Hybrid AI, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insights into real-world applications of artificial intelligence (AI) in preclinical cancer drug research. Attendees will learn best practices for implementing a hybrid AI approach to drug design. The featured speakers will discuss how to use AI/machine learning (ML) to determine first-in-human (FIH) dosing way faster, achieve better risk mitigation and/or achieve better initial dose selection compared to traditional methods.
TORONTO, May 15, 2024 Bringing a new drug to market costs far too much and takes far too long — and for cancer treatments especially, there is inherent urgency around getting these life-saving medications to patients faster. Antibody-drug conjugates show tremendous promise as a more selective therapy modality. But, as the industry investigates more conjugates and payload combinations, the expansion of preclinical research and experimentation is exploding.
Can adding artificial intelligence (AI) to the drug discovery and development process help manage the combinatory scale challenge posed by antibody-drug conjugates? Are all AI approaches the same? What challenges will teams face and how can they be overcome when adopting different AI approaches to their research and development plans? What can drug developers realistically expect in terms of worthwhile outcomes?
What challenges will teams face and how can they be overcome when adopting different AI approaches to their research and development plans?
In this webinar, the expert speakers will discuss how VeriSIM Life and Debiopharm partnered to scalably investigate first-in-human (FIH) dosing strategies for antibody-drug conjugates to reduce tumor burden safely and effectively. Topics explored will include:
The speakers will also share details right from the first step of evaluating a technology partner to the implementation of the solution and the results.
Register for this webinar to discover the transformative role of AI in accelerating antibody-drug conjugate development for cancer treatment.
Join Dr. Jo Varshney, PhD, DVM, CEO, VeriSIM Life; and Dr. Annick Menetrey, PhD, Clinical Pharmacology Lead, Debiopharm, for the live webinar on Thursday, May 30, 2024, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Accelerating Clinical Translation of Antibody-Drug Conjugates with Hybrid AI.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/